Application of Emerging Technologies for Cancer Research

The summary for the Application of Emerging Technologies for Cancer Research grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Application of Emerging Technologies for Cancer Research: The National Cancer Institute (NCI) invites applications for research projects to evaluate the usefulness of emerging technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements. Projects should also be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus. It is expected that some refinement or adaptation of the technology may be appropriate in the initial phase of the project, but projects requiring significant technology development effort are not appropriate. In addition, applications that propose the use of commercially available technology under standard conditions, or any technology that is already commonly accepted for the proposed use, are not appropriate. (Applicants proposing projects focused on biological or clinical questions are encouraged to contact their program director to discuss appropriate funding opportunities). This initiative is part of a broader technology development program within the NCI. That program underscores the desire of NCI to develop and integrate novel technologies focused on the molecular analysis of cancers and their micro-environment in support of cancer research, diagnosis, and treatment. In the research continuum of discovery, development, and delivery, this program thus emphasizes the link between development and delivery. This specific initiative will serve as a tool to develop emerging technologies in an appropriate biological or clinical context. This RFA capitalizes on both the success and intent of the original NCI sponsored Innovative Molecular Analysis Technologies (IMAT) program in bringing together a multi-disciplinary group of scientists and engineers to work on cancer and the expansion of interest in technology development across the NCI and other NIH institutes. This continuation of the IMAT program consists of the following three initiatives: Innovative Technologies for the Molecular Analysis of Cancer; Innovations in Cancer Sample Preparation; and Application of Emerging Technologies for Cancer Research. This RFA is designed to replace and expand on the Applications of Innovative Technologies for the Molecular Analysis of Cancer (PAR-01-106). It will support studies which start with an unproven technology, adapt or refine the technology slightly as needed, and begin to generate biological data to assess the relative robustness of the technology in the chosen biological or clinical context. Projects requiring significant technology development may be most suitable for RFA CA-05-002, Innovative Technologies for the Molecular Analysis of Cancer ( 002.html). Technologies developed or adapted for sample preparation methodology may be most suitable for RFA CA-05-004, Innovations in Cancer Sample Preparation ( 004.html). Applicants from small businesses are encouraged to submit applications to the parallel RFA for each IMAT initiative which utilizes the SBIR and STTR grant mechanisms (see MECHANISM OF SUPPORT). Applications of in vivo imaging technologies and projects with bioinformatics or statistics as their primary focus are not included under this RFA. Researchers who emphasize the assessment of in vivo imaging technologies as the primary focus of their grant application should contact the Cancer Imaging Program ( ) for information on appropriate funding opportunities. Researchers focusing on applying new bioinformatics or statistical techniques as the primary focus of their application should consider one of the BISTI initiatives (
Federal Grant Title: Application of Emerging Technologies for Cancer Research
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-05-003
Type of Funding: Grant
CFDA Numbers: 93.39293.393
CFDA Descriptions: Cancer Construction 93.393 Cancer Cause and Prevention Research
Current Application Deadline: No deadline provided
Original Application Deadline: February 17, 2004; June 17, 2004; October 18, 2004
Posted Date: Dec 23, 2003
Creation Date: Dec 23, 2003
Archive Date: Nov 17, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: 93.394 -- Cancer Detection and Diagnosis Research
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2020